Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of innovative therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is co... Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of innovative therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The firm's pipeline includes investigational product candidates that affect heme biosynthesis and iron metabolism. Mehr anzeigen
Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for...
Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80 million available at Disc’s sole discretion...
Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) Poster presentations across all programs, including updates from ongoing clinical studies and...
Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the...
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3.175 | 5.28418074395 | 60.085 | 68.73 | 57.91 | 531255 | 64.92132267 | CS |
| 4 | 15.49 | 32.4262089177 | 47.77 | 68.73 | 44.81 | 444505 | 55.19521242 | CS |
| 12 | 14.19 | 28.9178724271 | 49.07 | 68.73 | 44.69 | 280105 | 52.2524531 | CS |
| 26 | 32.45 | 105.322947095 | 30.81 | 68.73 | 30.65 | 318268 | 45.96289804 | CS |
| 52 | 14.63 | 30.0843100966 | 48.63 | 77.6 | 25.6 | 345109 | 47.6263156 | CS |
| 156 | 42.37 | 202.824317855 | 20.89 | 77.6 | 15 | 259080 | 46.10167935 | CS |
| 260 | 42.37 | 202.824317855 | 20.89 | 77.6 | 15 | 259080 | 46.10167935 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
